Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
16 Agosto 2024 - 8:01AM
- Independent analytical testing of Bentrio for > 230
prohibited substances of WADA list found none of them
- Outcome further confirms Bentrio’s
suitability for use by athletes in protection against airborne
allergens or other particles
Altamira Medica Ltd. (“Altamira” or the
“Company”), an associate company of Altamira Therapeutics Ltd.
(Nasdaq:CYTO), today announced that its preservative-free,
drug-free Bentrio® nasal spray for allergic rhinitis was tested
successfully for the absence of more than 230 prohibited substances
listed by the World Anti-Doping Agency (WADA). This finding further
confirms Bentrio’s suitability for athletes who must comply with
antidoping regulations but at the same time need to protect
themselves against airborne allergens or other particles.
“Many athletes have to walk a tightrope when
seeking to legitimately prevent allergic rhinitis or find relief
from allergy symptoms while avoiding inadvertent conflicts with
antidoping regulations”, commented Thomas Meyer, Altamira's
founder, Chairman, and CEO. “With today’s sensitive analytical
methods, athletes may for example trigger positive doping test
results when taking treatments or supplements which are
contaminated with prohibited substances. Or in other cases, the
treatment or supplement may contain a substance which is permitted
when taken with certain products, but prohibited when taken in
other forms, e.g. through a different administration route.”
The case of Lennert Van Eetvelt, a young
professional Belgian cyclist, illustrates the possible consequences
of testing inadvertently positive for a prohibited substance.1 In
2023, Van Eetvelt was temporarily placed on non-active racing
status for ‘alleged breach of anti-doping laws’ after AFLD, the
French anti-doping authority, had decided to investigate his
(declared) use of an allergy nasal spray. His treatment contained a
substance which is banned when taken in pill-form or via an
injection but permitted when taken in spray form. The cyclist was
ultimately cleared of the allegation, but the inquiry had shut him
out of competitions for three weeks.
Mr. Meyer added: “By its design as a drug-free
and preservative-free nasal spray which acts by forming a
protective barrier on the nasal mucosa, and by the choice of
ingredients, Bentrio is already well suited for compliant use by
athletes. The rigorous screening of Bentrio for a standard panel of
prohibitive substances by one of the world’s leading anti-doping
laboratories, which showed negative results across the board,
further confirms its suitability for athletes.”
About Bentrio
Bentrio is an “over the counter” drug-free nasal
spray for personal protection against airborne allergens and, where
approved, against airborne viruses. Upon application into the nose,
Bentrio forms a protective gel layer on the nasal mucosa. This thin
film is designed to prevent the contact of airborne particles with
cells; in addition, the composition serves to bind such particles
and help with their discharge. The efficacy and safety of Bentrio
has been demonstrated in a total of four clinical trials, of which
the largest one (“NASAR” study) enrolled 100 patients suffering
from seasonal allergic rhinitis. In NASAR, participants
self-administered either Bentrio or saline nasal spray for two
weeks 3 x per day. The study showed a statistically significant
reduction in the mean daily reflective Total Nasal Symptom Score
(rTNSS) for Bentrio compared to saline (p = 0.013), as well as a
statistically highly significant improvement in health-related
quality of life (Rhinoconjunctivitis Quality of Life Questionnaire,
p < 0.001) and superior global ratings of efficacy by patients
and investigators alike (p < 0.001). In addition, Bentrio showed
good safety and tolerability, similar to saline controls, and fewer
Bentrio treated patients used relief medication and more of them
enjoyed symptom-free days compared to saline treatment. For more
information, visit: www.bentrio.com
About Altamira Therapeutics
Altamira Therapeutics (Nasdaq: CYTO) is
developing and supplying peptide-based nanoparticle technologies
for efficient RNA delivery to extrahepatic tissues (OligoPhore™ /
SemaPhore™ platforms). The Company currently has two flagship siRNA
programs using its proprietary delivery technology: AM-401 for KRAS
driven cancer and AM-411 for rheumatoid arthritis, both in
preclinical development beyond in vivo proof of concept. The
versatile delivery platform is also suited for mRNA and other RNA
modalities and made available to pharma or biotech companies
through out-licensing. In addition, Altamira holds a 49% stake
(with additional economic rights) in Altamira Medica AG, which
holds its commercial-stage legacy asset Bentrio®, an OTC nasal
spray for allergic rhinitis. Further, the Company is in the process
of partnering / divesting its inner ear legacy assets. Founded in
2003, Altamira is headquartered in Hamilton, Bermuda, with its main
operations in Basel, Switzerland. For more information, visit:
https://altamiratherapeutics.com/
Forward-Looking Statements
This press release may contain statements that
constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements are statements other than historical
facts and may include statements that address future operating,
financial or business performance or Altamira’s strategies or
expectations. In some cases, you can identify these statements by
forward-looking words such as "may", "might", "will", "should",
"expects", "plans", "anticipates", "believes", "estimates",
"predicts", "projects", "potential", "outlook" or "continue", or
the negative of these terms or other comparable terminology.
Forward-looking statements are based on management's current
expectations and beliefs and involve significant risks and
uncertainties that could cause actual results, developments and
business decisions to differ materially from those contemplated by
these statements. These risks and uncertainties include, but are
not limited to, the clinical utility of Altamira’s product
candidates, the timing or likelihood of regulatory filings and
approvals, Altamira’s intellectual property position and Altamira’s
financial position. These risks and uncertainties also include, but
are not limited to, those described under the caption "Risk
Factors" in Altamira’s Annual Report on Form 20-F for the year
ended December 31, 2023, and in Altamira’s other filings with the
Securities Exchange Commission (“SEC”), which are available free of
charge on the SEC’s website at: www.sec.gov. Should one or more of
these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those indicated. All forward-looking statements and all
subsequent written and oral forward-looking statements attributable
to Altamira or to persons acting on behalf of Altamira are
expressly qualified in their entirety by reference to these risks
and uncertainties. You should not place undue reliance on
forward-looking statements. Forward-looking statements speak only
as of the date they are made, and Altamira does not undertake any
obligation to update them in light of new information, future
developments or otherwise, except as may be required under
applicable law.
Investor Contact:
Hear@altamiratherapeutics.com
1
https://www.cyclingnews.com/news/van-eetvelt-returns-to-racing-but-remains-indignant-over-nasal-spray-case/
Altamira Therapeutics (NASDAQ:CYTO)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Altamira Therapeutics (NASDAQ:CYTO)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
